2011 Archive


Partnership Focused on Developing Drugs Targeting the Th17 Pathway through the Inhibition of RORγt to Treat Autoimmune Diseases ANN ARBOR, Mich. – December 21, 2011 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has reached the first milestone under its research… Read More

ANN ARBOR, Mich. – October 4, 2011 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that Kathleen M. Metters, Ph.D., former senior vice president and head of worldwide basic research at Merck, has been named president and chief executive officer and a member… Read More

PLYMOUTH, Mich. – September 7, 2011 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that the company will present at the following industry conferences this fall: BioPharm America™ 2011, being held Sept. 7-9 at the Westin Boston Waterfront in Boston. Gary D. Glick,… Read More

PLYMOUTH, Mich. – March 27, 2011 – Lycera Corporation, a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that the company presented at the following industry conferences: Society for Biomolecular Sciences (SBS) 17th Annual Conference and Exhibition, held March 27-31 in Orlando, Fla. Xiao Hu, Ph.D., senior… Read More

Companies to Focus on Developing Drugs that Inhibit RORγt PLYMOUTH, Mich. – March 3, 2011 – Lycera Corporation, a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has entered into an exclusive research collaboration with Merck to discover, develop and commercialize small molecules that target… Read More

Findings Demonstrate Lycera’s Compound Selectively Silences Pathogenic Cells and Arrests Graft-Versus-Host Disease PLYMOUTH, Mich. – January 26, 2011 – Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced positive data from the University of Michigan demonstrating the role of bioenergetics in selectively inhibiting pathogenic… Read More